In a report published by Tsuji et al. [21], CD34+ cell therapy was explored for cerebral ischemia, showing the benefits of intravenous administration of human umbilical cord blood (hUCB)-CD34+ cells in a mouse model of neonatal stroke, including improved blood flow and reduced loss of ipsilateral hemispheric volume [7]. The gene discussed is CD34; the disease is Stroke.